Business Wire

Ventus Therapeutics to Present at the Stifel 2023 Healthcare Conference

WALTHAM, Mass. & MONTREAL--(BUSINESS WIRE)--Ventus Therapeutics, a clinical-stage biopharmaceutical company utilizing structural biology and a proprietary computational chemistry platform to develop a robust pipeline of novel medicines in immunology, inflammation, and neurology, announced today that its President and Chief Executive Officer Marcelo Bigal, M.D., Ph.D., will present at the Stifel 2023 Healthcare Conference in New York.



Dr. Bigal’s presentation will take place on Wednesday, November 15, 2023 at 9:45 AM ET.

About Ventus Therapeutics
Ventus Therapeutics is a clinical-stage biopharmaceutical company deploying leading-edge structural biology and computational chemistry tools to create novel small molecule medicines for challenging targets in immunology, inflammation, and neurology. The company’s proprietary drug discovery platform, ReSOLVE™, gives it the ability to discover and develop medicines through unique insights into protein targets and to create dynamic hydrocophore™ blueprints that can guide the development of differentiated therapies at a fast pace. Ventus’ first target screen was conducted in 2020, which led to the nomination of three development candidates in 2022, including: VENT-03, a potential first-in-class cGAS inhibitor; VENT-02, a brain-penetrant NLRP3 inhibitor; and VENT-01, a peripherally restricted NLRP3 inhibitor. Ventus entered the clinic with its most advanced program, VENT-02, in 2023, and the Phase 1 clinical trial is ongoing. These programs exemplify Ventus’ unique discovery capabilities and focus on first- and best-in-class programs for multi-indication immunology and neurology targets. For more information, please visit www.ventustx.com and engage with Ventus on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements about future expectations, plans, and prospects, including, but not limited to, statements related to the anticipated benefits of Ventus’ business strategy, pipeline programs, drug discovery platform, and financial position. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements due to the risks and uncertainties inherent in Ventus’ business, which include, without limitation, the timing, progress, and results of preclinical and clinical studies involving its development programs; the results of its earlier studies not being predictive of future results; its ability to enhance the ReSOLVE™ platform; its ability to continue to obtain funding for its operations and to implement its business strategy; the impact of the COVID-19 pandemic on its business; anticipated developments related to its competitors and its industry; the performance of third-party service providers, including suppliers, manufacturers, and CROs; and its ability to obtain, maintain, and protect its intellectual property. Any forward-looking statements contained in this press release speak only as of the date hereof, and Ventus undertakes no duty or obligation to update any forward-looking statements as a result of new information, future events, or otherwise.


Contacts

Media
Alexis Feinberg
ICR Westwicke
203-939-2225
Alexis.Feinberg@westwicke.com

READ ON BUSINESS WIRE

Back

Latest News

Subscribe to the BAM Newsletter

Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.

Subscribe